Presented here is a unified description of techniques that can be used to develop, transform, administer, and test heterologous protein expression of the probiotic yeast Saccharomyces boulardii.
Development of recombinant oral therapy would allow for more direct targeting of the mucosal immune system and improve the ability to combat gastrointestinal disorders. Adapting probiotic yeast in particular for this approach carries several advantages. These strains have not only the potential to synthesize a wide variety of complex heterologous proteins but are also capable of surviving and protecting those proteins during transit through the intestine. Critically, however, this approach requires expertise in many diverse laboratory techniques not typically used in tandem. Furthermore, although individual protocols for yeast transformation are well characterized for commonly used laboratory strains, emphasis is placed here on alternative approaches and the importance of optimizing transformation for less well characterized probiotic strains. Detailing these methods will help facilitate discussion as to the best approaches for testing probiotic yeast as oral drug delivery vehicles and indeed serve to advance the development of this novel strategy for gastrointestinal therapy.
Probiotic microorganisms are an intriguing potential means of efficiently and economically delivering heterologous proteins to the gastrointestinal tract. These organisms are capable of surviving passage through the gastrointestinal tract yet do not colonize it1, enabling controlled dosing and limiting exposure to the drug expressed. Furthermore, the ability to easily engineer these organisms to produce heterologous protein on a large scale renders them an economical alternative to synthetic delivery particles. However, development of such an approach, as recently demonstrated using an auxotrophic strain of the probiotic yeast Saccharomyces boulardii2, requires knowledge of laboratory techniques not traditionally combined within a given study, ranging from yeast and molecular biology to animal handling techniques and immunological methods. Thus although the individual procedures described herein are not in themselves novel laboratory protocols, the goal of this manuscript is to present a unified introduction to techniques needed for experimental testing of probiotic yeast as drug delivery vehicles to the murine gastrointestinal tract. Provided is a compilation of essential protocols for: 1) generation of auxotrophic mutant strains of yeast that can easily be genetically manipulated; 2) transformation of yeast cultures to express heterologous protein; 3) administration of recombinant yeast to the intestine via oral gavage; and 4) recovery of viable recombinant probiotic yeast from the murine intestine and assessment of their heterologous protein expression.
First, although numerous positive and negative selection methods exist for the manipulation of yeast species, negative selection such as through the use of auxotrophic markers increases both the efficiency and ease with which yeast can be transformed and selected. Positive selection of transformants using antibiotics, in contrast, significantly increases the cost of yeast manipulation. Furthermore, selection of yeast on antibiotic-containing solid media can allow for increased growth of untransformed background colonies relative to selection of auxotrophic yeast on synthetic drop out solid media (unpublished observations). Auxotrophic yeast is strains which lack enzymes critical for the synthesis of essential amino acids or uracil. Such yeast can grow only if supplemented with the missing metabolite or metabolic gene, thus enabling negative selection when yeast is plated onto synthetic drop out media that lacks the essential metabolite. Many commonly used Saccharomyces cerevisiae laboratory strains are in fact already auxotrophic mutants3. Industrial, clinical, and probiotic yeast strains, however, are typically prototrophic with the ability to synthesize all required nutrients. To enable more efficient genetic manipulation of such yeast, auxotrophic genes can be selectively targeted to generate strains that can be selected without antibiotics. Specific targeting of auxotrophic marker genes can be achieved through PCR-mediated gene disruption relying on homologous recombination or more recently through CRISPR/Cas9 targeting4–6. Alternatively, UV mutagenesis can quickly generate auxotrophic mutants even in yeast strains for which transformation with multiple plasmids is technically difficult7. While PCR targeting and CRISPR/Cas9 have been described extensively elsewhere, presented in part one of this manuscript is a detailed protocol describing a UV mutagenesis approach to create auxotrophic strains that will allow for negative selection rather than positive antibiotic selection of yeast transformants.
The next necessary step in the use of such auxotrophic strains for oral delivery of heterologous protein is yeast transformation with plasmid DNA. Since the first successful transformation of yeast spheroplasts reported for Saccharomyces cerevisiae in 19788, numerous modifications have been characterized to increase the efficiency and ease with which yeast species can be genetically modified. Use of electroporation for the successful transformation of DNA into S. cerevisiae was first described in 19859 and has since been improved via the addition of 1 M sorbitol incubation to osmotically support cells10. Electroporation efficiency has furthermore been shown to depend on the yeast species and strain, cell number and phase of growth, electroporation volume, field strength, and specific buffers11. Lithium acetate (LiOAc) transformation, originally described by Ito et al.12, is among the most commonly used transformation protocols as it requires no special equipment. Additional analyses showed that the efficiency of LiOAc yeast transformation greatly increases when cells are collected in mid-log phase of growth and are heat shocked in the presence of polyethylene glycol (PEG) and DNA at 42 °C12. Incubation of whole intact yeast with PEG is essential for efficient transformation, possibly through improving attachment of DNA to the cell membrane as well as via other effects on the membrane13. Lithium itself also increases the permeability of intact cells14. Although most laboratory S. cerevisiae strains can easily be transformed using LiOAc transformation3, other yeast species may be more efficiently transformed using alternative protocols. Pichia pastoris, for example, is most efficiently transformed via electroporation rather than LiOAc transformation13. It is crucial, therefore, to test multiple methods of transformation and to optimize incubation periods and reagent concentrations when attempting to genetically modify an uncharacterized yeast strain. This manuscript thus describes both LiOAc transformation and electroporation as techniques for the transformation of auxotrophic mutant and wild type S. boulardii. Interested readers are directed to recent reviews for thorough descriptions of the evolution of yeast transformation, alternative protocols, and further discussions of possible mechanisms of action13,15. Transformation of yeast with plasmid encoding an easily detectable protein is furthermore essential for downstream testing in order to ensure proper expression and function of heterologous protein. Myriad different proteins may be selected depending on the ultimate purpose of the therapeutic study and the antibodies available for protein detection by immunoblotting, ELISA, and other techniques. Protocols for these techniques have been thoroughly described elsewhere16,17, and can be used to determine levels of heterologous protein production from transformed yeast by comparison to standard curves. For purposes of demonstration and to show successful production of a very commonly used protein in yeast biology, this manuscript presents transformation with plasmid encoding green fluorescent protein (GFP), which allows for subsequent detection using fluorescence microscopy.
Equally important to the production of probiotic organisms that express heterologous protein is the proper administration and detection of these microorganisms within gastrointestinal tissues, as described in parts three and four. Administration of recombinant yeast via oral gavage allows for delivery of controlled quantities of yeast directly into the stomach, from which C57BL/6 mice are naturally incapable of vomiting18. However, improper animal handling and gavage can lead to esophageal damage and perforation, gastric perforation, tracheal administration, and aspiration pneumonia19,20. Poor technique and inexperience can furthermore increase variability in murine immune responses and experimental results, which have been attributed to animal stress upon oral gavage21,22. Practice in the proper technique can thus not only attenuate animal discomfort, but can also increase precision of experimental results. This manuscript describes and demonstrates animal handling and oral gavage for the administration of controlled doses of recombinant yeast.
Finally, it is vital to confirm successful delivery of recombinant yeast by analyzing lymphoid tissues for the presence of yeast and heterologous protein. The gastrointestinal immune tissues which can most easily and predictably be examined for the presence of yeast are the Peyer's patches. Peyer's patches are secondary lymphoid organs along the small intestine that are key sites of mucosal immune response induction23. Antigens from the lumen are transferred transcellularly through microfold (M) cells in the epithelium and are released into the Peyer's patches, thus exposing enclosed antigen presenting cells to intestinal luminal contents. Although particle uptake across the intestinal epithelium can also be achieved by goblet cells, these cells have been shown to only take up particles less than 0.02 µm in diameter24. Transepithelial dendrites extended from CD103+ dendritic cells (DC) also take up small particles from the intestinal lumen25; however, there are currently no reports demonstrating that CD103+ DCs take up particles larger than bacteria. Thus, intact probiotic yeast, of average size between 3-6 µm in diameter, are most likely to be taken up by M cells and transferred to the Peyer's patches. Described here is a protocol for collection and screening of Peyer's patches for viable recombinant yeast, although this procedure can also be easily adapted for evaluating uptake of probiotic bacteria.
In summary, assessing recombinant probiotic yeast for the delivery of therapeutic proteins to the intestine requires proficiency in laboratory techniques spanning molecular biology to animal handling and immunology. Presented here are protocols for 1) the generation and screening of auxotrophic yeast strains which can be easily negatively selected without antibiotics, 2) alternative protocols to transform yeast and enable expression of heterologous protein, 3) demonstrations of proper animal handling techniques and oral gavage for intragastric delivery of recombinant yeast, and 4) protocols for Peyer's patch dissection and screening for viable recombinant yeast and functional heterologous protein. Combined, these protocols will allow for the generation and testing of a probiotic yeast strain capable of delivering heterologous therapeutic protein to the gastrointestinal tract.
1. UV Mutagenesis to Generate Auxotrophic Yeast Strains
2. Yeast Transformation
3. Oral Gavage of Mice with Transformed Yeast
4. Harvest of Murine Peyer's Patches and Isolation of Viable Yeast Colonies
Generation of a survival curve following UV irradiation requires plating of diluted yeast cells such that distinct colony forming units (CFU) are able to form. Each 500 µl sample collected as described above contains approximately 5 x 106 cells; however, greater than 100 colonies per plate are difficult to accurately distinguish. Plating undiluted sample as well as serial 1:10 dilutions of irradiated cells thus ensures that CFU can be enumerated at each UV dose, as demonstrated in Figure 1. The CFU count, multiplied by the dilution factor, is then divided by the total number of original irradiated cells in each 500 µl sample in order to determine percent survival at each dose. Figure 2 shows the calculated percentage of diploid wild type S. boulardii cells able to survive 0 µJ, 5,000 µJ, 10,000 µJ, 15,000 µJ, 20,000 µJ, 22,500 µJ, 25,000 µJ, 35,000 µJ, and 50,000 µJ. These data establish a clear curve that can be used to find the dose corresponding to 50% survival.
After selection of UV dose and irradiation of yeast cells, it is critical to screen mutant colonies to confirm lack of a functional auxotrophic marker gene. Use of a selection method, as described in 1.2.3.1 and shown in Figure 3, significantly increases the efficiency of phenotype confirmation. Shown is an example of URA3 selection that takes advantage of the conversion of 5-FOA to the toxin 5-FU by intact Ura3. Analogous approaches are available for LYS2 and LYS5; TRP1; and MET2 and MET15 and increase efficiency of selection for these mutations. Care must be taken to select individual colonies during screening. The consistent growth of mutant colonies on YPD and 5-FOA, but not uracil–, plates indicates auxotrophic phenotype.
Figure 4 shows transformation efficiency for wild type S. boulardii (S.b.) relative to a commonly used laboratory S. cerevisiae strain (S.c.) using both the LiOAc (LiOAc) and electroporation (Electro) techniques. Although LiOAc transformation is very efficient for S. cerevisiae, transformation efficiency for S. boulardii is greatly improved using electroporation. Figure 5 shows use of fluorescence microscopy as an example method of analyzing proper protein expression from transformed yeast. Brightfield (A) and fluorescence (B) images are shown for S. cerevisiae transformed with a URA3 plasmid encoding GFP, demonstrating functional expression of heterologous protein from the transformed yeast. Cells can be immobilized for better visualization using coverslips coated in concanavalin A (coat 5 µl of a 2 mg/ml stock solution in water onto each 22 x 22 µm coverslip and air dry).
Figure 6A shows a C57BL/6 mouse held just prior to oral gavage. The hand grasps the back and neck of the mouse firmly such that the mouse is not able to move the head in any direction. This hold allows the gavage needle to be placed accurately and with decreased risk of tissue damage. Figure 6B shows the gavage needle held after the mouse swallows the gavage needle. Following the incubation period, the small intestine of the sacrificed mouse should be carefully teased apart from the surrounding tissues, as shown in Figure 7. This manipulation allows for easy identification of Peyer's patches and for clean dissection of the patches without collecting any of the surrounding lamina propria. Finally, Figure 8 shows typical recovery of viable yeast CFU from Peyer's patches.
Solutions | Yeast Media and Plates | Transformation Reagents |
Polyethylene glycol (PEG) 50%: | YPD: | TE/LiOAc: |
250 g PEG 3350 | 20 g peptone | 50 ml 10x TE |
500 ml sterile water | 20 g dextrose | 50 ml 10x (1M) LiOAc |
Filter sterilize | 10 g yeast extract | 400 ml sterile water |
1 L water | Filter sterilize | |
Autoclave | ||
TE 10x: | YPD plates: | PEG/TE/LiOAc: |
100 mM Tris | 20 g peptone | 400 ml 50% PEG |
10 mM EDTA | 20 g dextrose | 50 ml 10x TE |
pH to 7.5 and filter sterilize | 20 g agar | 50 ml 10x (1M) LiOAc |
10 g yeast extract | ||
1 L water | ||
Autoclave | ||
20% glucose: | Uracil– selective media | Carrier DNA (SS DNA): |
200 g dextrose | 2 g amino acid mix lacking uracil | Store at -20 °C and prior to use heat for 1-2 min at 100 °C to melt strands and store on ice |
1 L water | 6.7 g yeast nitrogen base without amino acids | |
Filter sterilize | 1 L water | |
Sterilize by autoclaving or sterile filtering | ||
Add 20% glucose 1:10 before use | ||
50% glycerol: | Uracil– plates: | Electroporation buffer: |
500 ml glycerol | In a 250 ml flask: | 1 M Sorbitol |
500 ml water | 2 g amino acid mix lacking uracil | 1 mM CaCl2 |
Autoclave | 6.7 g yeast nitrogen base without amino acids | Fill with distilled water |
150 ml water | Autoclave and store at 4 °C | |
In a 2 L flask: | ||
20 g agar | ||
750 ml water | ||
Autoclave flasks separately, then mix together with 100 ml 20% glucose | ||
Complete IMDM | 5-FOA+ plates: | LiOAc/DTT |
500 ml Iscove's Modified Dulbecco's Media | Autoclave in a 2 L flask: | 0.1 M LiOAc |
5 ml penicillin streptomycin glutamine 100x | 20 g agar | 10 mM DTT |
500 μl 2-mercaptoethanol | 750 ml water | |
10% heat inactivated fetal bovine serum | Mix: | |
2.5 ml sodium pyruvate 100 mM | 6.7 g yeast nitrogen base without amino acids | |
2 g amino acid mix without uracil | ||
150 ml warm water | ||
When cool, add: | ||
0.05 g uracil powder | ||
1 g 5-FOA | ||
Stir and filter sterilize | ||
Add to autoclaved agar solution | ||
Mix with 100 ml 20% glucose |
Table 1. Reagents List. Described are the reagents needed for making each of the solutions, yeast media and plates, and transformation buffers used for the protocols in this manuscript.
Figure 1. Yeast colonies grown on YPD media. Example YPD plate showing viable colony forming units (CFU) of probiotic yeast after UV irradiation. Cells were serially diluted such that individual CFU can be distinguished and counted. Please click here to view a larger version of this figure.
Figure 2. Survival curve for diploid probiotic yeast. Number of viable S. boulardii CFU as a percent of total plated cells was plotted for each µJ dose of UV irradiation (solid line). The vertical red line indicates the µJ UV dose corresponding to 50% survival of this yeast strain. A rad1 S. cerevisiae mutant, which cannot repair damage from UV mutagenesis, is shown as a control (dashed line). Please click here to view a larger version of this figure.
Figure 3. Confirmation of ura3– phenotype of UV irradiated cells on YPD, uracil–, and 5-FOA plates. Cells from individual UV mutant colonies were collected using the tip of a sterile toothpick and gently streaked across YPD, uracil–, and 5-FOA plates. Cells were first streaked in two perpendicular crossing lines, then a new toothpick was used to pass through the second line and continue spreading cells until individual cells separate. A true ura3– mutant (mut) grows on YPD media and in the presence of 5-FOA, but not in the absence of uracil. Control ura3– S. cerevisiae (ura3–) and URA3+ S. boulardii (URA3+) are shown for comparison and to confirm proper preparation of yeast media. Please click here to view a larger version of this figure.
Figure 4. Transformation Efficiency of Saccharomyces strains. Wild type S. boulardii (S.b.) and a laboratory S. cerevisiae strain (S.c.) were transformed using the described LiOAc (LiOAc) and electroporation (Electro) protocols. Results are plotted as mean CFU obtained per µg of plasmid encoding a kanamycin resistance marker. Bars show the mean of duplicate experiments with error bars depicting the standard error of the mean. Please click here to view a larger version of this figure.
Figure 5. Functional Protein Expression by Transformed Yeast. S. cerevisiae transformed with empty plasmid (A) and plasmid encoding GFP (B) were analyzed using a fluorescent microscope. Fluorescence in the yeast cells transformed with GFP plasmid indicates successful production of functional GFP. Please click here to view a larger version of this figure.
Figure 6. Proper handling of a C57BL/6 mouse for oral gavage. The mouse is held tightly in the non-dominant hand with the tail tucked under the small finger so that no movement is possible (A). The gavage needle is inserted into the pharynx along the roof of the mouth. The mouse is allowed to swallow the bulb of the gavage needle, allowing the solution to then enter the stomach as the plunger is depressed (B). Please click here to view a larger version of this figure.
Figure 7. Preparation and dissection of Peyer's patches. The small intestine is shown dissected away from the other internal organs and tissue, with arrows pointing to a few of the Peyer's patches. Please click here to view a larger version of this figure.
Figure 8. Yeast Recovery from Peyer's Patches. An example of viable CFU detected after dissection, homogenization, and plating of total Peyer's patch cells from a mouse gavaged with S. boulardii. Cells were plated onto YPD yeast media and incubated at 30 °C for 2 days. Typical yield of CFU recovered per mouse is less than 10. Please click here to view a larger version of this figure.
Together, the protocols herein describe the essential steps necessary for the development and testing of auxotrophic probiotic yeast strains for delivery of heterologous therapeutic protein to the intestine. This manipulation and testing of recombinant probiotic yeast requires techniques and resources with which any individual laboratory may not currently be familiar. Thus, although numerous previous studies have described the above protocols for multiple yeast and mouse strains, these methods have not to the authors' knowledge been presented in a detailed, unified form. Furthermore, the present manuscript places particular emphasis on adapting current standardized protocols for the genetic manipulation of probiotic yeast, which are less well characterized than commonly used laboratory yeast strains. Many steps for both mutagenesis (discussed in part 1) and transformation (part 2) must be optimized for the manipulation of such diploid, probiotic yeast isolates. This manuscript also discusses potential pitfalls associated with animal handling (part 3) and dissection of the Peyer's patch immune tissues of the small intestine (part 4).
As many industrial and clinically relevant yeast strains are not immediately adaptable to large-scale genetic manipulation, it is first necessary to generate strains such as auxotrophic mutants that can be grown and selected without expensive antibiotics. UV mutagenesis is one such approach that allows for quick nonspecific mutation of auxotrophic genes7,41. Survival curves can easily be generated (Figures 1 and 2) to determine the appropriate dose for screening mutants. However, this approach carries the risk of inducing off target mutations that may affect growth rate or other properties of the yeast strain. Targeted knockouts can instead be generated using PCR constructs or the CRISPR/Cas9 system. Subsequent screening or selection (Figure 3) of mutants allows for identification of auxotrophic yeast. Use of selection by plating onto 5-FOA media, for example, allows for rapid elimination of any yeast still containing a functional URA3 auxotrophic gene. When possible, this selection approach may be preferable to a screen, which requires analysis of all colonies generated. With either selection or screening, however, it is critical to perform repeated streaking of individual yeast colonies onto selective media to confirm auxotrophic status.
Transformation of the generated mutants can be accomplished through different protocols. Although LiOAc transformation is effective in the transformation of many yeast strains, particularly for the most commonly used laboratory S. cerevisiae strains, alternative protocols such as electroporation may transform other yeast isolates with greater efficiency (Figure 4). Each new strain should be tested using multiple protocols to determine the optimal conditions for transformation. Varying incubation times and concentration of DNA, for example, can influence overall transformation efficiency and should be tested and optimized for each strain33.
Oral gavage allows for the delivery of controlled doses of these recombinant yeast directly to the murine gastrointestinal tract, whose immune tissues can then be assayed for yeast and heterologous protein. Proper oral gavage technique (Figure 6) is critical to minimize animal discomfort and increase experimental precision. Furthermore, the Peyer's patches are key sites to assess uptake of recombinant yeast from the intestine. These clusters of immune tissue are important sites of antigen sampling and induction of mucosal immune responses. Large antigens, including yeast 3-6 µm in diameter, are most likely to be taken up by the M cells of Peyer's patches in order to cross the gastrointestinal epithelium and interact with immune cells. Care must be taken when dissecting the Peyer's patches to ensure that only cells from within the patch rather than the intestinal lumen or lamina propria are collected (Figure 7). Further steps must also be taken following dissection to assess proper expression and function of heterologous protein in the recovered yeast (Figure 8). Preparation of total protein from yeast lysates and immunoblotting is one standard method to assess protein expression; however, this approach does not provide information regarding protein folding and function. To assess protein function, yeast can be transformed with a plasmid encoding GFP and analyzed under a fluorescent microscope after recovery from Peyer's patches to assess functional GFP expression (Figure 5).
In sum, this manuscript presents a unified set of detailed experimental protocols spanning steps from the generation of auxotrophic mutants to the recovery of probiotic yeast from the murine intestine. By compiling protocols that do not traditionally fall within a single area of expertise, these descriptions will facilitate further studies testing immunological responses to probiotic yeast designed as oral drug delivery vectors. The authors hope this study will encourage discussion and promote optimization of experimental methods for each yeast strain tested, paving the way for the most efficient approaches to the development of novel, probiotic-based recombinant therapies.
The authors have nothing to disclose.
The authors acknowledge funding through the Children's Center for Immunology and Vaccines and an NIH New Innovator Award (1DP2AI112242-01) awarded to Tracey J. Lamb. The authors also thank Natalya P. Degtyareva for the generous contribution of rad1 S. cerevisiae.
SmartSpec 3000 Spectrophotometer | BioRad | 170-2501 | Example of spectrophotometer for determining cell concentration and OD600 of yeast cultures |
New Brunswick Roller Drum | Eppendorf | M1053-4004 | Example of roller drum for yeast culture incubation |
UV Stratalinker 2400 | Stratagene | 400075-03 | Example stratalinker |
Stuart Colony Counter SC6PLUS | 11983044 | Fisher Scientific | Plate stand with magnification records colony count upon sensing pressure from pen |
Scienceware Colony Counter | F378620002 | Bel-Art Scienceware | Hand held colony counter pen |
Replica plating device | Fisherbrand | 09-718-1 | Example of replica plating stand and pads |
Velveteen squares | Fisherbrand | 09-718-2 | |
L shaped sterile cell spreaders | Fisherbrand | 14665230 | |
Deoxyribonucleic acid, single stranded from salmon testes | Sigma-Aldrich | D7656-1ML | Example carrier DNA for yeast LiOAc transformation |
Gavage needles | Braintree Scientific | N-PK 002 | For mice 15-20 g, the suggested needle is a 22 gauge (1.25 mm ball), 1 in long, straight reusable gavage needle. For mice weighing greater than 20 g, 20 gauge or larger straight or curved gavage needles may be used |
1mL sterile slip-tip disposable tuberculin syringe | Becton Dickinson | BD 309659 | |
Blunt forceps such as Electron Microscopy Sciences 7" (178 mm) serrated tip, broad grip forceps | Electron Microscopy Sciences | 77937-28 | Example of blunt forceps needed for dissection |
Straight and curved dissection scissors | Electron Microscopy Sciences | 72966-02 and 72966-03 | Examples of scissors needed for dissection |
IMDM | Life technologies | 12440053 |